APTENSIO XR
Clinical safety rating: caution
Comprehensive clinical and safety monograph for APTENSIO XR (APTENSIO XR).
Central alpha-2 adrenergic agonist that selectively stimulates alpha-2 adrenergic receptors in the brain stem, reducing sympathetic outflow and decreasing peripheral vascular resistance, heart rate, and blood pressure.
| Metabolism | Primarily hepatic via CYP3A4 and CYP3A5 isoenzymes; also undergoes glucuronidation and hydroxylation. |
| Excretion | Methylphenidate is primarily excreted renally as metabolites (80-90%), with 1-3% excreted unchanged. Biliary/fecal elimination accounts for <5%. |
| Half-life | The terminal elimination half-life of methylphenidate (IR and extended-release) is approximately 3-4 hours in children and 3.5-5 hours in adults. For Aptensio XR, the half-life is about 4-5 hours, supporting twice-daily dosing. |
| Protein binding | Methylphenidate is approximately 15-25% bound to plasma proteins (primarily albumin). |
| Volume of Distribution | The volume of distribution for methylphenidate is 2.65 L/kg (range 1.8-4.0 L/kg) in children and 2.2 L/kg in adults, indicating extensive tissue distribution. |
| Bioavailability | Oral bioavailability of methylphenidate is low and variable, approximately 11-52% due to extensive first-pass metabolism. Aptensio XR is designed for extended release; absolute bioavailability is similar to IR formulations. |
| Onset of Action | Aptensio XR: Onset of clinical effect occurs within 30-60 minutes after oral administration, with peak plasma concentrations at 1-4 hours (due to dual-pulse delivery). |
| Duration of Action | Aptensio XR provides clinical effects for approximately 10-12 hours after oral administration, allowing once-daily dosing for ADHD management. |
Oral, 20 mg once daily in the morning; may increase by 10–20 mg/day at 3-day intervals up to a maximum of 60 mg/day.
| Dosage form | CAPSULE, EXTENDED RELEASE |
| Renal impairment | No specific GFR-based dose adjustments are recommended; use with caution in severe renal impairment (CrCl <30 mL/min) due to increased exposure. |
| Liver impairment | Child-Pugh Class A and B: Reduce starting dose to 10 mg once daily; titrate cautiously. Child-Pugh Class C: Not recommended. |
| Pediatric use | Approved for children ≥6 years: starting dose 0.07–0.14 mg/kg (max 5 mg) once daily; titrate by 0.07 mg/kg (max 5 mg) at weekly intervals; maximum 0.28 mg/kg or 20 mg/day. |
| Geriatric use | Initiate at 10 mg once daily; titrate in increments of 10 mg/day at 3-day intervals due to increased sensitivity and risk of adverse effects. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for APTENSIO XR (APTENSIO XR).
| Breastfeeding | Methylphenidate is excreted into human breast milk. The milk-to-plasma ratio (M/P) is approximately 0.1-0.2. Relative infant dose is estimated at 0.2-0.7% of maternal weight-adjusted dose. Limited data suggest low risk, but monitor infant for agitation, insomnia, and decreased weight gain. Consider benefits of breastfeeding versus potential infant exposure. |
| Teratogenic Risk | Methylphenidate is classified as Pregnancy Category C. Insufficient human data; animal studies show increased incidence of fetal anomalies at high doses. Risk cannot be ruled out. Use only if potential benefit justifies potential risk. First trimester: theoretical risk of teratogenicity; second and third trimesters: risk of fetal tachyarrhythmia, growth restriction, and neonatal withdrawal symptoms including irritability, feeding difficulties, and respiratory distress. |
■ FDA Black Box Warning
None.
| Serious Effects |
["History of hypersensitivity to clonidine or any component of the formulation."]
| Precautions | ["May cause sedation, somnolence, and drowsiness; caution driving or operating machinery.","Risk of hypotension, bradycardia, syncope; monitor blood pressure and heart rate.","Rebound hypertension upon abrupt discontinuation; taper dose.","QTc interval prolongation at high doses; avoid in patients with congenital long QT syndrome or history of cardiac arrhythmias.","Avoid use with alcohol or other CNS depressants.","Hepatic impairment may require dose reduction."] |
| Food/Dietary | Food does not affect the overall bioavailability of APTENSIO XR but may delay the time to peak concentration. Avoid high-fat meals close to dosing as they can alter absorption profile. Avoid alcohol, which can cause premature release of the drug and increase side effects. Grapefruit and grapefruit juice have not been specifically studied but should be avoided due to potential CYP3A4 inhibition affecting metabolism. |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood pressure, heart rate, and weight gain throughout pregnancy. Assess fetal growth via ultrasound every 4-6 weeks during second and third trimesters. Perform nonstress test or biophysical profile in third trimester if concerns arise. Monitor neonatal outcomes for withdrawal symptoms or adverse effects post-delivery. |
| Fertility Effects | In animal studies, high doses of methylphenidate caused decreased spermatogenesis and impaired fertility. Human data are limited; reports suggest reversible effects on male fertility (sperm count and motility) with long-term use. No definitive evidence of female fertility impairment, but individual cases of menstrual irregularities reported. |
| Clinical Pearls | APTENSIO XR is a long-acting methylphenidate formulation with a unique bimodal release profile via a delayed-release and extended-release mechanism (DEX-MPH). It is designed to be swallowed whole; crushing or chewing destroys the extended-release properties. Onset of action is approximately 1 hour, with a duration of up to 12 hours. Monitor for growth suppression in pediatric patients; height and weight should be measured at baseline and every 6 months. Avoid use in patients with glaucoma, motor tics, or family history of Tourette's syndrome. Due to risk of serotonin syndrome, avoid coadministration with MAOIs within 14 days. Use with caution in patients with hypertension, hyperthyroidism, or history of drug abuse. |
| Patient Advice | Take APTENSIO XR once daily in the morning with or without food. Swallow the capsule whole; do not crush, chew, or open it. · Do not take the medication later than 10 AM to avoid nighttime sleep disturbances. · Avoid alcohol while taking this medication, as it can alter the drug release and increase side effects. · Store at room temperature (59-86°F) away from moisture and heat. · Common side effects include decreased appetite, trouble sleeping, headache, and stomach upset. Contact your doctor if you experience chest pain, shortness of breath, or signs of allergic reaction. · This medication has a high potential for abuse and dependence; keep in a secure place and do not share with others. · Regular monitoring of blood pressure, heart rate, height, and weight is needed during treatment. |